{"id":"ly2963016","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LY2963016 is a biosynthetic insulin glargine designed to provide steady, long-acting glycemic control in diabetes patients. It mimics endogenous insulin by activating insulin receptors on muscle and adipose tissue, facilitating glucose uptake and suppressing hepatic glucose production. The formulation is engineered for extended duration of action to reduce dosing frequency.","oneSentence":"LY2963016 is a long-acting basal insulin analog that binds to the insulin receptor to regulate blood glucose by promoting glucose uptake and storage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:23.058Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04153981","phase":"PHASE4","title":"A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":304},{"nctId":"NCT04864977","phase":"PHASE4","title":"A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Eli Lilly and Company","startDate":"2021-08-16","conditions":"Type 2 Diabetes, Type 2 Diabetes Treated With Insulin","enrollment":""},{"nctId":"NCT03338010","phase":"PHASE3","title":"A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-03-22","conditions":"Type 2 Diabetes","enrollment":536},{"nctId":"NCT03338023","phase":"PHASE3","title":"A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-03-23","conditions":"Type 1 Diabetes","enrollment":272},{"nctId":"NCT03555305","phase":"PHASE1","title":"A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-09-26","conditions":"Healthy","enrollment":58},{"nctId":"NCT02302716","phase":"PHASE3","title":"A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-12","conditions":"Diabetes Mellitus, Type 2","enrollment":493},{"nctId":"NCT02955953","phase":"PHASE1","title":"A Study Comparing Two Formulations of Insulin Glargine in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-11-14","conditions":"Healthy","enrollment":127},{"nctId":"NCT01421459","phase":"PHASE3","title":"A Study in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-09","conditions":"Diabetes Mellitus, Type 2","enrollment":759},{"nctId":"NCT01421147","phase":"PHASE3","title":"A Study in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-08","conditions":"Diabetes Mellitus, Type 1","enrollment":536},{"nctId":"NCT01634165","phase":"PHASE1","title":"A Study of LY2963016 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT01374178","phase":"PHASE1","title":"A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-06","conditions":"Diabetes Mellitus","enrollment":16},{"nctId":"NCT01476345","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-11","conditions":"Diabetes Mellitus","enrollment":80},{"nctId":"NCT01600950","phase":"PHASE1","title":"A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 1","enrollment":20},{"nctId":"NCT01688635","phase":"PHASE1","title":"A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-09","conditions":"Healthy","enrollment":91}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LY2963016","genericName":"LY2963016","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LY2963016 is a long-acting basal insulin analog that binds to the insulin receptor to regulate blood glucose by promoting glucose uptake and storage. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}